BioCentury
ARTICLE | Clinical News

Ironwood's linaclotide meets in OIC study

December 1, 2015 3:11 AM UTC

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said linaclotide ( ASP0456) met the primary endpoint in a Phase II trial to treat adults with opioid-induced constipation.

The trial included 254 patients with chronic, non-cancer pain who had been receiving a stable dose of an opioid analgesic and had fewer than three spontaneous bowel movements (SBM) per week. Once-daily 145 ug and 290 ug doses of linaclotide met the primary endpoint of a greater frequency of SBM over eight weeks vs. placebo. ...